Shares of Monopar Therapeutics Inc. (MNPR), a clinical-stage radiopharmaceutical company, are currently up over 450% at $25, following an agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, a late-stage Wilson disease drug candidate.
Alexion, AstraZeneca Rare Disease is a research group within AstraZeneca (AZN) focused on rare diseases. It was created in 2021 after AstraZeneca acquired Alexion Pharmaceuticals Inc. for $39 billion or $175 per share.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com